Minocycline is proposed as an add-on therapy to improve the efficacy of glatiramer acetate (Copaxone)
Minocycline is proposed as an add-on therapy to improve the efficacy of glatiramer acetate in relapsing-remitting multiple sclerosis. The effect of minocycline plus glatiramer acetate was evaluated in this double-blind, placebo-controlled study.Mult Scler. 2009 Sep 23 epub ahead of print
Canadian researchers, lead by Dr. Luanne Metz of Calgary,aimed to investigate the efficacy of combined glatiramer acetate(GA) plus minocycline treatment in people with relapsing-remitting MS, by comparing a group receiving GA plus minocycline with another receiving GA plus placebo. Forty-four participants were randomized to either minocycline 100 mg twice daily or matching placebo for 9 months as add-on therapy. They were assessed at screening and months 1, 3, 6, 8 and 9. Forty participants completed the study.
Compared with glatiramer acetate/placebo, glatiramer acetate/minocycline reduced the total number of T1 gadolinium-enhanced lesions by 63%, the total number of new and enlarging T2 lesions by 65%, and the total T2 disease burden. A higher number of gadolinium-enhanced lesions were present in the glatiramer acetate/minocycline group at baseline; this was incorporated into the analysis of the primary endpoint but makes interpretation of the data more challenging. The risk of relapse tended to be lower in the combination group.
Treatment was safe and well tolerated. The authors conclude that results showed a consistent trend favouring combination treatment.
As minocycline is a relatively safe oral therapy, The authors conclude that further study of this combination is warranted in relapsing-remitting multiple sclerosis.
Source: Multiple Sclerosis Society of Canada (14/10/09)
Treatment: Gilenya since 01/2011, CCSVI both IJV ballooned 09/2010, Tysabri stopped after 24 Infusions and positive JCV antibody test, after LDN, ABX Wheldon Regime for 1 year.